Axolotl Biologix - Acquired by Carmell Corporation (CTCX) a Nasdaq listed company
BiotechnologyView the employees at
Axolotl Biologix - Acquired by Carmell Corporation (CTCX) a Nasdaq listed company-
Greg Burnett Financial Executive
-
Top 5%
Brandon Merriweather Field Specialist at Axolotl Biologix I help give your practice a competitive advantage-
Rising Star
Eric Lee Director of Research and Training at Axolotl Biologix-
Phoenix, Arizona, United States
-
Rising Star
Robert G. Audet Senior Research Scientist at Carmell Therapeutics-
Flagstaff, Arizona, United States
-
Top 5%
Alexander Marquez Controller-
Greater Phoenix Area
-
Top 10%
Overview
Axolotl Biologix, Inc. was acquired in August 2023 by Carmell Corporation, a Nasdaq listed company (CTCX). Carmell is developing allogeneic plasma-based biomaterials designed to boost innate regenerative pathways across a variety of skin and bone healing indications. Carmell received FDA clearance for a Phase 2-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding and is planning a Phase 2 trial for Foot/Ankle Fusion. Pre-clinical development is also underway in Spinal Fusion, Dental Bone Graft Substitute, Androgenetic Alopecia, Active Soft Tissue Repair and Cosmetic Skin Rejuvenation. For more information, visit www.carmellrx.com
-